Latest Commentary

Payer revolt notwithstanding, Gilead's Sovaldi earns crown as fastest drug launch ever

We can officially say that Gilead Sciences pulled off the fastest drug launch on record. First-quarter sales of the company's new hepatitis C drug Sovaldi (sofosbuvir), approved in December, blew past previous records and just kept going. And along the way, it broke the blockbuster barrier, too.

GlaxoSmithKline and Novartis, starring players in a Big Pharma deal bonanza

While the chattering classes were chattering about a potential Pfizer-AstraZeneca merger yesterday, three other drug giants were putting the finishing touches on a big announcement. Novartis, whose strategic review has been making headlines for almost a year, agreed to swap some assets with GlaxoSmithKline and sell its animal health business to Eli Lilly.

Vivus needs more than boardroom shuffling to keep up with Arena's Belviq

One pre-First Manhattan Co.-settlement Vivus director standing for re-election at the company's annual meeting, that is. The Mountain View, CA-based drugmaker announced Tuesday in a regulatory filing that J. Martin Carroll, Mark Logan and Robert Wilson would not seek to retain their board positions.

If GSK's chief wants to be Mr. Clean, he needs to get out the broom

GlaxoSmithKline says it's rolling out sales and marketing reforms around the world. Apparently, the changes come none too soon. The British drugmaker opened another bribery investigation, this time in Iraq, to check out allegations that it paid government-employed physicians to promote its products.

Amarin triples size of Vascepa sales force with Kowa promo deal

It hasn't been easy being Amarin over the last several months. The Irish drugmaker slammed into one obstacle after another. Read more from FiercePharmaMarketing>>

Are pricey cancer drugs worth the cost? ASCO means to find out

Public debate over high drug prices is one thing. But pushback from doctors is something else altogether. And when those doctors happen to be in charge at the American Society of Clinical Oncology, drugmakers might want to start worrying.

Don't bet on a home-run drug launch, even for power-hitting drugs

Two-thirds of new drugs fall short of expectations their first year on the market and continue to fall short after that. But McKinsey & Co. consultants found that good launches are very, very good. What makes the difference? The consulting firm took a close look at 60 different drug launches to find out.

Big Data's double-edged sword: Better drug marketing, bigger SG&A cost cuts

Big Data could be a big deal for Big Pharma's commercial operations. It could help top drugmakers slash another $35 billion-plus in costs over the next several years, to keep margins up. But it's small drugmakers that could benefit most strategically, a new report finds.

Who loses most in Lilly vs. Novo diabetes study? AstraZeneca

Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza.

Thumbs up or down on megamergers? Depends on your point of view

These days, "merger of equals" is the preferred term, and some companies are on the lookout. Others, particularly R&D types who've lived through integrations they'd rather forget, decry the idea. The pro-and-con debate rages on.